Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Aug 14, 2020 · 10-Q · 45 days after period end · 0001213900-20-022334
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Net Income | -$4.63M | -$5.03M | -$4.86M | -$7.05M |
| EPS Diluted | -$0.41 | -$1.00 | -$0.04 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end
